DRG Market Assessment reports

Parkinson’s disease (PD) treatment is complex; the disease is heterogeneous, requiring individualized treatment and frequent adjustments to achieve symptom control. New therapies that address PD…

Fewer than ten new brands have launched in the highly generic and crowded Parkinson’s disease (PD) therapy market during the past two decades, but PD’s large and growing elderly population and…

Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly; DRG forecasts PD prevalence to grow 2% annually in the major pharmaceutical markets through…

Parkinson’s disease (PD) treatment is complex; the disease is heterogeneous, requiring individualized treatment and frequent adjustments (e.g., in dosing, in regimens) to achieve symptom control…

Last Updated 16 December 2015 Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly; its prevalence is expected to grow 2% annually in the major…

European Physician and Payer Perspective on Current Mainstays and Novel Entrants in the Age of Austerity Parkinson’s disease (PD) is a debilitating chronic neurodegenerative disease affecting…

The symptomology of Parkinson’s disease (PD) is heterogeneous; individual patients experience different combinations of primary motor symptoms, complications of therapy, and/or key nonmotor…

In a Market of Entrenched, Effective, and Mostly Generic Therapies, Where Do Physicians and Payers Identify Areas for Differentiation? The prevalence of Parkinson’s disease (PD) will approach…

The symptomology of Parkinson’s disease (PD) is heterogeneous; individual patients experience different combinations of primary motor symptoms, complications of therapy, and/or key nonmotor…

Last Updated 29 September 2014 Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly, and its prevalence is expected to grow 2% annually as the…